Helene Finney, PhD

Director, Functional Screening at UCB

Speaker

Helene joined UCB (then Celltech) in 1989 and has gained
expertise in a range of antibody technologies. Her PhD studies
at UCB in gene therapy generated the first co-stimulation
signal inclusive (now termed “second generation”) CAR-T
cell constructs. She has led a variety of antibody technology
teams & early stage therapeutic antibody discovery projects
for oncology, bone, immunology/inflammation & CNS
targets. Helene now leads the UCB Functional Screening
project team; combining cutting edge antibody & screening
technology to discover break-through bispecific antibody
drugs across multiple therapeutic areas.